Ikena Oncology Inc

Research Ikena Oncology Inc (IMA) on Bullrun: market cap USD 68.46M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 68.46M
• Financial periodFY2025
• RevenueUSD 800.00K
• Revenue growth-77.1%
• Net income-USD 45.35M

Valuation Snapshot

latest market cap is USD 68.46M.

About Ikena Oncology Inc

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc.

Frequently asked questions

What is Ikena Oncology Inc's market cap?

Ikena Oncology Inc's market capitalization is USD 68.46M.

What does Ikena Oncology Inc do?

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.